General

Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers. Santo L et al. Semin Oncol. 2015 Dec;42(6):788-800. doi: 10.1053/j.seminoncol.2015.09.024. Epub 2015 Sep 24. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults. Guerard EJ et al. Clin Geriatr Med. 2016 Feb;32(1):191-205. doi: 10.1016/j.cger.2015.08.012. Epub 2015 Oct 9. Multiple myeloma and physical activity: a scoping review. Smith L et al. BMJ Open. 2015 Nov 27;5(11):e009576.…

Complications of myeloma and its treatments

A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment. Liu A et al. Acta Haematol. 2015 Nov 21;135(3):140-145. [Epub ahead of print]. CD4(+)CD25(+) cells in multiple myeloma related renal impairment. Huang H et al. Sci Rep. 2015 Nov 13;5:16565. doi: 10.1038/srep16565. Complications after surgery for metastatic humeral lesions. Janssen SJ et al. J Shoulder Elbow Surg. 2015 Nov 4. pii: S1058-2746(15)00446-2. doi: 10.1016/j.jse.2015.08.009. [Epub ahead…

Current treatments

Evaluation of low-dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation. Aznab M et al. Asia Pac J Clin Oncol. 2015 Nov 4. doi: 10.1111/ajco.12418. [Epub ahead of print]. Phase 3 trial of three thalidomide-containing regimens in patients with newly diagnosed multiple myeloma not transplant-eligible. Hungria VT et al. Ann Hematol. 2015 Oct 30. [Epub ahead…

Diagnostic tests and prognostic indicators

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy. Siontis B et al. Blood Cancer J. 2015 Oct 23;5:e364. doi: 10.1038/bcj.2015.87. 18F-FDG PET/CT FOCAL, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Zamagni E et al. Leukemia. 2015 Oct 22. doi: 10.1038/leu.2015.291. [Epub ahead of print]. MMSA-1 expression pattern in multiple myeloma and…

Related conditions

TCL1 expression patterns in Waldenström macroglobulinemia. Lemal R et al. Mod Pathol. 2015 Oct 23. doi: 10.1038/modpathol.2015.122. [Epub ahead of print]. Cast nephropathy: an extremely rare renal presentation of Waldenström’s macroglobulinaemia. Santos T et al. BMJ Case Rep. 2015 Oct 7;2015. pii: bcr2015211210. doi: 10.1136/bcr-2015-211210. Severe peripheral neuropathy following carfilzomib, rituximab, and dexamethasone for initial treatment of Waldenström’s macroglobulinemia. Alfaraj WA et…

Emerging treatments

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. Mu S et al. Eur J Clin Pharmacol. 2015 Oct 22. [Epub ahead of print]. Panobinostat for the treatment of multiple myeloma: the evidence to date. Bailey H et al. J Blood Med. 2015 Oct 8;6:269-76. doi: 10.2147/JBM.S69140. eCollection 2015. Panobinostat for the treatment of relapsed…

Biology and genetics

Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma. Ludwig C et al. Blood Cancer J. 2015 Oct 16;5:e359. doi: 10.1038/bcj.2015.85. Impact of cytogenetic classification on outcomes following early high dose therapy in multiple myeloma. Kaufman GP et al. Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.287. [Epub ahead of print]. Insight into human…

General

Clarification on the definition of complete response in multiple Myeloma. Durie BG et al. Leukemia. 2015 Oct 21. doi: 10.1038/leu.2015.290. [Epub ahead of print]. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.…